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It is lay knowledge now that Alzheimer’s dementia (AD) is one
of the most devastating diseases afflicting our societies. A
major thrust in search for a curehas relied in thedevelopment
of animal models of the disease. Thanks to progress in the
genetics of the rare inherited forms of AD, various transgenic
mouse models harboring human mutated proteins were de-
veloped, yielding very significant advancements in the un-
derstanding of pathological pathways. Although thesemodels
led to testing many different new therapies, none of the pre-
clinical successes have translated yet into much needed ther-
apeutic improvements. Further insight into themetabolic dis-
turbances that are probably associated with the onset of the
disease may also rely on new animal models of AD involving
insulin/IGF-I signaling that couldmimic the farmost common
sporadic forms of AD associated with old age. Combination of
models of familial AD that develop severe amyloidosis with
those displaying defects in insulin/IGF-I signaling may help
clarify the link between putative initial metabolic distur-
bances and mechanisms of pathological progression. (Endo-
crinology 149: 5952–5957, 2008)
AMAJOR GOAL in biomedicine is to obtain useful exper-imental models of human diseases. Naturally, in vivo
models mimicking all the clinical traits of the target disease are
the ideal setting. Most available models of human disease do
not reach this golden standard, but for several important dis-
eases, a reasonably good approximation has been achieved.
This is the case for transgenic mouse models of Alzheimer’s
dementia (AD), one of themain causes of disability anddeath
in the elderly (1). Current Alzheimer models rely on infor-
mation gathered from inherited forms of the disease, far less
common than sporadic ones but indistinguishable from the
clinical point of view. Thus, both early familiar and late-onset
sporadic forms progressively develop cognitive deteriora-
tion that in early stages affect memory systems and at late
phases impair all cognitive spheres of daily life activities (2).
Similarly, the underlying neuropathology in the two forms
of the disease include extracellular deposits of -amyloid
(A) peptides, intraneuronal accumulation of aberrant forms
of hyperphosphorylated tau, a microtubule-associated pro-
tein, forming neurofibrillary tangles, and synapse and neu-
ronal loss. Many other pathological changes are present in
AD brains, but amyloid plaques and tangles, as originally
defined by Alzheimer (3), are universally considered the
traits that characterize the disease. Although the etiology of
AD remains unknown, these two characteristics are used for
the only established diagnosis of the disease presently avail-
able that relies on postmortem verification. Identification in
various human pedigrees of familial AD of mutations on the
amyloid precursor protein (APP), the transmembrane pro-
tein giving rise to A (4), and on presenilin-1 and -2, part of
themembrane enzymes involved inAPPprocessing (5), soon
led to the production of transgenic mice expressing these
human proteins and to many other genetically modified
models including ablation, knock-in, and compound geno-
types of these proteins (6).
The availability of these mouse models originated a wealth
of data on pathological mechanisms in AD. It is fair to say that
the majority of advances in AD have been made possible by
these models (7). Another very profitable use of these mice has
been to test new therapies including not only a diversity of
drugs but also vaccines or behavioral strategies. However, in
this case, the information obtained has met with somewhat
mixed success. This may be exemplified by the significant im-
provementobserved in transgenicmice receivingvarious forms
of A vaccines that turned into a clinical assay that had to be
halteddue tounexpected lethal effects (meningoencephalitis) of
the therapy (8). Although these tough lessons will hopefully
translate into better designed and safer clinical assays, includ-
ing new vaccine forms (9), the failure of these animalmodels to
yield not a single reliable clinical outcome has recently put into
question their utility as preclinical models of sporadic AD. Not
coincidentally, among many other new proposals, a novel po-
tential pathogenic route involving IGF-I, which in turn encom-
passes a former one that postulated impaired insulin function as
a major cause of sporadic AD, has recently gained attention (10).
In this review, I will summarize the main animal models
of AD based on genetic manipulation and describe the ad-
vancements that originated and their preclinical use. The
advent of new animal models based on a different etiopatho-
genic postulate involving metabolic disturbances in the
brains of AD patients will also be discussed and integrated
within current concepts of the causes of the disease.
Transgenic Mouse Models of AD
Transgenic mouse models harboring mutations found in
familial AD constitute themost widely used in vivo approach
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to study this disease. Few years elapsed between the de-
scription of a dominant missense APP mutation in familial
AD (11) and the generation of the first transgenic mouse
bearing amutated humanAPP (12) that effectivelymimicked
several AD features, with prior attempts with wild-type APP
made earlier (13). This testifies to the fast pace of this dy-
namic field. Indeed, the number of transgenic models of AD
bearing human mutations is now so large and the literature
produced so vast that only the major findings can be sum-
marized. A detailed account of the different mouse models
and their phenotypes may be found in various excellent
reviews (6, 14). Although invertebratemodels have also been
developed, because they do not constitute the mainstream of
research in AD models, they will not be further considered.
Probably themain observation arising frommousemodels
was that excess A elicits cognitive impairment even in the
absence of neurofibrillary tangles or neuronal loss (7). This
finding posed this pathological change as the main culprit
and therefore substantiated the amyloid cascade hypothesis
of AD that favors brain amyloidosis as the cause of the
disease (15). Consequently, the pathogenic contribution of
neurofibrillary tangles (16)was neglected. Later observations
combining various transgenic models concluded that the
extent of A plaque load does not correlate with cognitive
loss. This triggered a subsequent refinement of the amyloid
hypothesis that stipulated that soluble amyloid oligomers
rather than insoluble deposits are responsible for synapse
loss underlying the pathology (17). Presenilins are key com-
ponents of the -secretase complex that cleaves APP and
other transmembrane proteins (18). Most familial forms of
AD present with mutations in either presenilin-1 or -2 (PS1
or PS2), which appear to result in enhanced A production
(18). Although transgenic mice bearing human presenilin
mutations do not develop AD-like features unless they are
combined with APP mutations (14), the double conditional
PS1/PS2 mutant in adult brain provides the only mouse
model of familial AD that includes both cognitive loss and
neurodegeneration (19). Currently, double transgenics ex-
pressing mutant APP and either of the mutated presenilins
(PS1 or PS2) are the most widely used models. The reason is
that two main features of the disease, amyloidosis and cog-
nitive loss, develop very rapidly in these mice, making them
better suited for experimental studies (20).
Because none of the above models developed neurofibril-
lary tangles, the main neuropathological disturbance in AD
together with amyloid plaques, mouse models expressing
human taumutations were generated. These transgenicmice
did develop tangles. Most significantly, they also showed
cognitive disturbances together with neuronal loss (21). The
latter trait is characteristic of human AD but absent in amy-
loid models, However, these models lacked amyloid
plaques. In turn, combined expression of mutated forms of
tau with mutant APP provided the first AD models display-
ing the three main characteristics of the disease, intracellular
neurofibrillary tangles (tauopathy) together with cognitive
loss and amyloid plaques (22). These models have been ex-
tensively used to dissect out the pathogenic link between
amyloidosis and tauopathy, with no definitive conclusions
reached yet. However, a main conceptual drawback of these
latter models is that no mutations in tau have so far been
detected in familial AD. Rather, the mutated tau forms em-
ployed in these transgenic mice are found in frontotemporal
dementia, an inherited neurodegeneration that lacks amy-
loid deposits (23). Nevertheless, because tauopathy corre-
lates well with cognitive loss, a key role for this pathological
derangement is supported (23).
Together with a better mechanistic insight into the neu-
ropathology of AD, transgenic models provided a powerful
preclinical tool for new treatments. Unfortunately, and in
contradistinction to the great gain in pathogenic knowledge,
new treatments arising from this knowledge have not fol-
lowed the same fast pace of achievement (24). For instance,
the membrane protease -secretase (BACE) was first de-
scribed as a potential target in AD almost 10 yr ago, but no
successful treatment has yet arisen from this information
(25), and its utility as a drug target is now questioned (26).
Again, the list of potentially therapeutic compounds and
treatments tested in transgenic mice is so extensive that only
a brief summary of major conclusions is possible (see Ref. 27
for an update). Drugs used in preclinical tests fall into either
disease-modifying or symptomatic categories. The former
derivedmostly fromnew therapeutic targets unveiled in part
with transgenic models. For instance, detailed knowledge of
the routes leading toAproduction providednumerous new
druggable targets (28) aiming to reduce A production in
different manners. Additional approaches not focusing on
amyloid reduction are also wisely encouraged (29). Devel-
opment of symptomatic drugs, which are becoming less sup-
ported lately (30), derived from the relative success of ace-
tylcholinesterase inhibitors, the main marketed drugs in AD
that aimed to correct behavioral deficits. These drugs were
developed without a firm experimental/conceptual basis.
Currently, it is unlikely that new symptomatic drugs will be
approved as regulatory agencies seek robust biological sur-
rogates of new therapies.
Beyond the Amyloid Cascade Hypothesis: Metabolic
Disturbances in AD and Corresponding Animal
Models
Despite the unquestionable benefit that these geneticmod-
els have provided to a better understanding of pathogenic
processes in AD, we still have more questions than answers
of underlying pathogenic mechanisms. Probably the major
drawback of transgenic models is that very few of them
mimic extensive neuronal loss typical of AD. And those few
are not based in actual pathological changes seen in AD
patients. In addition, none of the available models have
helped to reach a comprehensive explanation of the origin of
the disease. That is, amyloidosis is clearly a key component
in AD, but its trigger, increased production, decreased deg-
radation, or faulty clearance, or a combination of these, and
its role as a causative agent in sporadic AD remains unde-
fined. For this reason, new hypotheses of the origin of the
disease and their corresponding animal models are bloom-
ing. For instance, loss of function of presenilins have been
claimed to explain both familiar and sporadic forms of AD
(18). The pathogenic contribution of the 4 isoform of apo-
lipoprotein E and its relation to cholesterol metabolism in
late-onset forms is also actively studied (31), together with
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the role of cholesterol in the etiology of AD (32). Other
processes such as calcium dysregulation, disturbed autoph-
agy, aberrant proteasome function, mitochondrial failure,
and many other alterations have been proposed as progres-
sion rather than causative factors in the pathological cascade.
A candidate etiological event in AD is impaired energy
balance in brain cells.Metabolic disturbances associatedwith
AD are becoming a subject of intense scrutiny because re-
gional deficits in glucose use are firmly established in AD
brains. As a matter of fact, brain imaging of glucose con-
sumption is probably the most reliable imaging-based diag-
nosis of the disease at present (33). Early observations indi-
cated a high prevalence of insulin resistance inAD (reviewed
in Ref. 34), which was recently postulated as an early prog-
nosis marker of the disease (35). Although still controversial
(36), type 2 diabetes has also been proposed to increase the
risk of AD (37), whereas altered glucose metabolism may be
an early sign of cognitive decline (38), and systemic levels of
insulin correlate with AD neuropathology (39). Many other
observations support a role of insulin dysregulation in AD,
as highlighted by the type 3 diabetes label recently assigned
to the disease (40). The underlying notion is that loss of
insulin function is the cause of the disease because insulin is
a key regulator of cell metabolism and is involved in higher
brain functions including cognition (41). Several animal
models reinforce this possibility. Thus, defects in insulin
signaling in IRS-2 knockouts present tau hyperphosphory-
lation in their brains (42), a defect also observed in strepto-
zotocin-diabetic animals (43). Moreover, brain-specific dele-
tion of the insulin receptor originated the same pathological
change in tau phosphorylation (44). A practical outcome of
these observations has been to test insulin and insulin sen-
sitizers (peroxisome proliferator-activated receptor agonists)
in AD patients. Initial results are encouraging, but more
detailed clinical studies are warranted (45, 46).
However, deficits in insulin signaling do not fully model
AD pathology (44). Consequently, additional or alternative
causes are sought. For instance, estrogen deficiency with
advancing age in women, leading to impairedmitochondrial
energy output, has been proposed as a key contributor to
metabolic imbalance in AD (47). This may help explain gen-
der differences in disease incidence and support a possible
use of steroid hormone therapy (48). An additional altered
process may be IGF-I signaling upstream of insulin dysregu-
lation because IGF-I and insulin functions are closely inter-
twined. While examining the action of IGF-I at the blood-
brain barrier (49), a link between circulating IGF-I and brain
amyloid was observed (50). Based on these findings, we
hypothesized that disturbances in IGF-I precedes altered
brain insulin actions (51). A detailed account of this hierar-
chical relationship can be found elsewhere (52). In essence,
disrupted signaling of systemic IGF-I into the brain (prob-
ably initiated at the blood-brain barrier as a consequence of
interactions between genetic background and environmental
factors) would lead to brain insulin dysregulation and neu-
ropathological changes typical of AD (Fig. 1). Noteworthy,
FIG. 1. Disrupted systemic IGF-I input to the brain may arise from a combined deficiency/resistance associated with 1) old age, 2) IGF-I/IGF-I
receptor polymorphisms, 3) various illnesses, or 4) lifestyle factors such as sedentary life, imbalanced diet, or stress. In turn, this originates
brain insulin-deficient signaling. Together with disturbed IGF-I input, reduced brain insulin functionmay lead to all pathological derangements
associated with AD that are classically attributed to amyloidosis in the amyloid cascade hypothesis (81).
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the majority of the neuroprotective pathways where IGF-I is
involved appear altered in AD (Table 1). Moreover, an an-
imal model based on this proposal mimicked late-onset AD
in rodents that included cognitive loss, tauopathy, and in-
creased A levels (53). This hypothesis predicted early in-
creases in serum IGF-I levels in AD patients (51), as recently
reported (54), together with a gradual decline at later phases
of the disease, also recently observed in AD (55). This pattern
may reflect a progressive process of resistance/deficiency of
IGF-I input to the brain (51, 56), also recently claimed to be
observed in AD brains (57) and reminiscent of the patho-
logical progressive insulin resistance/deficiency in type 2
diabetes. When combined with classical models of AD the
corresponding animal model helped to clarify the relative
contribution of plaque load and amyloid clearance to cog-
nitive derangement because enhanced clearance was suffi-
cient to ameliorate cognitive loss without any effect on
plaque load (58). This supports the emerging notion that
even in the absence of amyloid plaque-clearing effects, cog-
nitive improvement is possible.
This theoretical proposal provides a conceptual frame to
place findings obtained from the corresponding animalmod-
els. Thus, disrupted brain insulin signaling will lead to most
but not all AD pathology because a concomitant lesion in
IGF-I signaling is required. As the status of insulin and in-
sulin receptor levels in AD brain is controversial (57), a key
aspect of this proposal would be to determine the existence
of a pathway linking disrupted IGF-I signaling to reduced
insulin action. Although entirely speculative at present, var-
ious alternative, nonexclusive explanations are possible.
IGF-I may act as an insulin receptor cofactor, and its reduc-
tion will lead to altered insulin receptor signaling (59). In
addition, if indeed IGF-I receptor levels are increased in AD
(57), a possible resultant increase in IGF-I/insulin receptor
hybrids will originate loss of insulin action (60). Conversely,
an additional compounded pathway may lead to impaired
insulin action. First, reduced IGF-I input will lead to amyloid-
osis due to imbalanced Ametabolism (53, 61). Then, reduced
availability of insulin-degrading enzyme and impaired insulin
binding to its receptor will follow (62, 63). In addition, low
insulin-degrading enzyme levels will also contribute to insulin
resistance (64). Once IGF-I and insulin functions in the brain are
compromised, all pathological disturbances in AD will ensue
through processes such as oxidative stress or inflammation, as
discussed in detail elsewhere (51).
Notably, many observations combining metabolic and hor-
monal manipulations in classical transgenic mouse models of
AD conform to this proposal. For instance, the observed im-
proved cognition and pathology after exercise or environmen-
tal enrichment in mutant APP mice (65, 66) can be potentially
explained by enhanced brain IGF-I input under these condi-
tions (49, 67). Conversely, the aggravation of AD symptoms
in transgenic mice fed with imbalanced diets (68, 69), or the
beneficial effects of healthy diets (70, 71) explained by cor-
responding changes in insulin signaling in brain, can also be
secondary to initial changes in brain IGF-I input (72). New
proposed links between APP and glucose metabolism and
growth (73), or the higher risks to suffer AD in obese subjects
(74), add fuel to this argument. Furthermore, the purported role
of ovarianhormones indevelopmentofAD, as tested invarious
transgenic models (75, 76), could also be linked to disturbances
in IGF-I signalingbecause thisgrowth factor is intimately linked
to gonadal function (77) and also declines with age.
In conclusion, as more work is needed to establish the role
of metabolic disturbances in the etiology of AD, the com-
bined use of traditional transgenic mouse models with met-
abolic imbalances constitute a reasonable approach to gain
further insight into these processes.
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